Lexicon Pharmaceuticals Stock Price - LXRX

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
After Hours
Last Trade
Last: $ 3.55 ▼ -0.01 (-0.28%)
Company Name Stock Ticker Symbol Market Type
Lexicon Pharmaceuticals Inc LXRX NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.11 3.19% 3.56 3.75 3.4403 3.47 3.45 19:59:46
Bid Price Ask Price Spread Spread % News
3.44 3.55 0.11 3.1% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
11,551 3,720,596 $ 3.58 $ 13,315,458 2,749,281 1.125 - 11.51
Last Trade Time Type Quantity Stock Price Currency
19:49:21 formt 500 $ 3.55 USD

Lexicon Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 378.33M 106.27M $ -120.55M -1.14 - 104.27M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Lexicon Pharmaceuticals News

Loading Messages....

Latest LXRX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical LXRX Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week2.373.892.253.39257M1.1950.21%
1 Month1.363.891.222.69233M2.2161.76%
3 Months6.096.721.1252.32942M-2.53-41.54%
6 Months8.258.551.1253.23071M-4.69-56.85%
1 Year10.7411.511.1254.44191M-7.18-66.85%
3 Years18.9719.621.1259.3970777k-15.41-81.23%
5 Years1.4319.620.87.9114944k2.13148.95%

Lexicon Pharmaceuticals Description

Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising drug targets. Lexicon then designs and develops drugs for these targets, which cover a broad spectrum of therapeutic areas. Following a restructuring in January 2014, Lexicon focused efforts on two drugs: sotagliflozin in diabetes, which is partnered with Sanofi, and Xermelo (telotristat etiprate) in carcinoid syndrome, which is partnered with Ipsen outside the U.S. Early-stage programs include SGLT1 inhibitor LX2761 and neuropathic pain drug LX9211.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.